No quarterly revenue total was found in enGene Therapeutics Inc.'s SEC filings.
enGene Therapeutics Inc. (ENGN) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$18.9 million. As of Jul 31, 2026 it held $266.3 million in cash and investments and $7.9 million in total debt.
Revenue
—
Net income
$-32.50M
-12.1% vs year-ago quarter
Operating cash flow
$-18.95M
+26.1% vs year-ago quarter
Free cash flow
$-18.95M
+28.1% vs year-ago quarter
EPS
$-0.47
+17.5% vs year-ago quarter
Dividend per share
$0.00
Shares outstanding
67.02M
+30.9% vs year-ago quarter
Net cash
$258.40M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ENGN (Nasdaq), ENGNW (Nasdaq)
- Fiscal year ends
- October 31
- Incorporated in
- Canada (Federal Level)
- Headquarters
- Saint-Laurent
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1980845
- Former names
- enGene Holdings Inc. (until Mar 9, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Jul 31, 2026 |
Q2 FY2026 Apr 30, 2026 |
Q1 FY2026 Jan 31, 2026 |
Q4 FY2025 Oct 31, 2025 |
Q3 FY2025 Jul 31, 2025 |
|---|---|---|---|---|---|
| Operating income | -$34.0M | -$32.0M | -$31.2M | -$39.5M | -$29.9M |
| Net income | -$32.5M | -$30.2M | -$29.8M | -$37.9M | -$29.0M |
| Diluted EPS | -$0.47 | -$0.43 | $0.44 | -$0.74 | -$0.57 |
| Operating cash flow | -$18.9M | -$30.5M | -$28.9M | -$25.0M | -$25.6M |
| Free cash flow | -$18.9M | -$30.6M | -$29.1M | -$25.4M | -$26.3M |
| Total assets | $288.3M | $307.5M | $337.1M | $221.5M | $245.6M |
| Total liabilities | $58.0M | $52.4M | $55.6M | $53.8M | $44.9M |
| Stockholders' equity | $230.3M | $255.2M | $281.5M | $167.7M | $200.7M |
| Cash and investments | $266.3M | $285.2M | $312.5M | $202.3M | $224.9M |
| Total debt | $7.9M | $8.2M | $8.5M | $8.5M | $8.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Sep 8, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Results of operations
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Other events
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 17, 2026 | Jul 17, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 16, 2026 | Jul 15, 2026 |
| 8-K/A |
Amended current report
Exit or restructuring costs, Officer or director change
|
Jun 18, 2026 | Jun 16, 2026 |
All 267 enGene Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.